When patients were divided according to the level of CRP, it was worth noting that patients with elevated CRP had an additional chance of developing serious infections after receiving Tocilizumab (47.8% versus 11.8%, p=0.0204, Supplementary Figure 6A). Here, CRP is linked to infection.